Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18–64 years by Osman N. Yogurtcu, Patrick R. Funk, Richard A. Forshee, Steven A. Anderson, Peter W. Marks, Hong Yang

Get full text

Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine by Yoji Hoshina, Christopher Sowers, Virginia Baker

Subjects: Get full text

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS by A. Naficy, P. Pirrotta, A. Kuxhausen, J. Miller, B. Leav, A. Mwakingwe-Omari

“…In Seq, one SAE/AESI (pulmonary embolism) and one pIMD/AESI (cutaneous vasculitis) occurred 2 and 9 days postmRNA-1273 (before RZV administration), respectively, and were considered mRNA-1273-related by investigators. …”
Get full text

P1534: MRNA-1273 SARS-COV-2 VACCINE IN RECENTLY TRANSPLANTED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: CELLULAR AND HUMORAL IMMUNE RESPONSES AND BOOSTER EFFECT by Nil Albiol, Elionor Lynton-Pons, Olga Aso, Esther Moga, Lucía Gómez-Pérez, Jose Alejandre-Santiago, Mercè Triquell, Nerea Roch, Elisabeth Lázaro, Iria González, Joaquín López-Contreras, Albert Esquirol Sanfeliu, Jorge Sierra, Rodrigo Martino, Irene Garcia Cadenas

Get full text

Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization by Ficociello LH, Willetts J, Mullon C, Johnson C, Anger MS, Hymes JL

Subjects: “…dialysis · covid-19 · vaccination · antibody · mrna-1273 vaccine · booster…”
Get full text

Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review by Angel Shabu, Prasad S. Nishtala

Subjects: Get full text

Association Between Fever and Antibody Titer Trends After a Third Dose of the mRNA-1273 Vaccine by Naomi Matsumoto, Tomoka Kadowaki, Rumi Matsuo, Ayako Sasaki, Chikara Miyaji, Chigusa Higuchi, Masanori Nakayama, Yasue Sakurada, Hideharu Hagiya, Soshi Takao, Fumio Otsuka, Takashi Yorifuji

Subjects: Get full text

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape by Rituparna Das, Randall N. Hyer, Paul Burton, Jacqueline M. Miller, Barbara J. Kuter

Subjects: Get full text

Is a single COVID-19 vaccine dose enough in convalescents ? by Daniele Focosi, Andreina Baj, Fabrizio Maggi

Subjects: Get full text

Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine by Angel Shabu, Prasad S. Nishtala

Subjects: Get full text

Risk of herpes zoster following mRNA COVID-19 vaccine administration by Ana Florea, Jun Wu, Lei Qian, Bruno Lewin, Lina S. Sy, I-Chun Lin, Jennifer H. Ku, Hung Fu Tseng

Subjects: Get full text

IMUNOGENICIDADE DE UM PRIMEIRO REFORÇO COM BNT162B2 OU MRNA-1273 DE DOSE COMPLETA: UM ESTUDO RANDOMIZADO EM ADULTOS ≥75 ANOS (EU-COVAT-1) DO CONSÓRCIO VACCELERATE by Jon Salmanton-Garcia, Julia M. Neuhann, Jannik Stemler, Antonio Carcas, Samir Kumar-Singh, Alejandro García Leon, Franz König, Oliver A. Cornely

Subjects: “…COVID-19 vacina ARNm-1273 SARS-CoV-2 BNT162b2…”
Get full text

Side effects following first dose of COVID-19 vaccination in Ho Chi Minh City, Vietnam by Si Van Nguyen, Bay Thi Nguyen, Huong Nguyen Viet Duong, Phong Thanh Lenh, Kien Trung Tran, Hoa Minh Tran, Thanh Cong Nguyen, Dung Phuong Nguyen, My Ngoc Ta, Nhut Nguyen Minh Trieu, Nam Ba Nguyen, Hung Quang Tran, Son Thanh Tran, Raghu Rai, An Le Pham

Subjects: Get full text

Safety and efficacy of RNA vaccines: State of the art by A. V. Blagov, A. A. Bukaeva, V. V. Makarov, Z. V. Bochkaeva

Subjects: Get full text

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines by Khalid Hajissa, Ali Mussa

Subjects: Get full text

Temporal association between COVID-19 vaccination and Raynaud’s phenomenon: A case series by Marcus Lisy, Nikolaus Urban, Sophie Brunner-Ziegler, Benedikt Weber, Wolfgang M. Bauer, Eva Dassler, Renate Koppensteiner, Alessandra Handisurya

Subjects: Get full text

Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic by Masahiro Aoshima, Satoko Ohfuji

Subjects: Get full text

Atrial Fibrillation After mRNA-1273 SARS-CoV-2 Vaccination: Case Report with Literature Review by Chen CY, Hsieh MT, Wei CT, Lin CW

“…Thus, before administering mRNA-1273 vaccines to patients with a history of valvular heart disease or atrial fibrillation, the patients’ cardiologists must be consulted.Keywords: atrial fibrillation, valvular heart disease, COVID-19 vaccination, case report…”
Get full text

Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients by Bruno Fattizzo, Bruno Fattizzo, Marta Bortolotti, Marta Bortolotti, Nicolò Rampi, Nicolò Rampi, Francesca Cavallaro, Francesca Cavallaro, Juri Alessandro Giannotta, Cristina Bucelli, Ramona Cassin, Matteo Claudio Da Vià, Matteo Claudio Da Vià, Giulia Galassi, Alessandro Noto, Loredana Pettine, Francesca Gaia Rossi, Mariarita Sciumè, Ferruccio Ceriotti, Dario Consonni, Wilma Barcellini, Luca Baldini, Luca Baldini

“…Patients (N = 393) received either BNT162b2 (Pfizer-BioNTech, 48%) or MRNA-1273 (Moderna, 52%), and 284 (72%) seroconverted and 100% persisted at 3 months. …”
Get full text